Previous 10 | Next 10 |
home / stock / nvmdf / nvmdf news
TORONTO, ON / ACCESSWIRE / January 5, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the "Design Concept") to accommodate the unique requiremen...
Novamind (OTCPK:NVMDF) will acquire Arizona-based mental health practice Foundations for Change from its sole shareholder Jeff Edelman. The firm will fund the acquisition, expected to close in January, with a combination of cash, shares and assumed debt. Within 30 days of closi...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / December 23, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novam...
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing mental health disorders. More and more psychedel...
Novamind Inc. (CSE: NM)(OTCQB: NVMDF) has opened a new clinic located in downtown Salt Lake City to address addiction. The SLC Clinic specializes in integrative behavioral health and services for adults with substance use disorders led by incoming Medical Director, Dr. Amy de la G...
Salt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza TORONTO, ON / ACCESSWIRE / December 6, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased ...
TORONTO, ON / ACCESSWIRE / December 2, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will present at the virtual H.C. Wainwright 2 nd Annual Psychedelics Conference on December 6, 2...
Strategic investment and advisory agreement enables the global expansion of Novamind's psychedelic clinic model TORONTO, ON / ACCESSWIRE / December 1, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in ps...
Novamind (OTCPK:NVMDF): Q1 GAAP EPS of -C$0.07. Revenue of C$1.85M (+112.6% Y/Y) Press Release Debt-free balance sheet with C$5.96M in cash and C$2.01M in marketable securities For further details see: Novamind reports Q1 results
Novamind (OTCPK:NVMDF): FQ1 GAAP EPS of -$0.07. Revenue of $1.86M (+113% Y/Y) Press Release Total working capital of $6.83M to fund operations. For further details see: Novamind reports FQ1 results
News, Short Squeeze, Breakout and More Instantly...
The pressure is ramping up on the U.S. Drug Enforcement Administration (DEA) as more lawyers, clinicians, researchers, investors and business owners working in the psychedelics industry are demanding clear answers about how the DEA should be evolving on its drug scheduling and e...
TORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Welln...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Numinus shareholders, at a separate meeting held today, have also approved the resolutions related t...